Articles related to CLINICAL TRIALS

A phase 3 clinical trial of solanezumab, an antibody that targets monomeric amyloid, showed no significant slowing of cognitive decline in patients with preclinical Alzheimer’s disease over 240 weeks, despite decreased brain amyloid levels.

Explore this comprehensive study examining the cognitive effects of the MIND diet in older adults with a predisposition to dementia, highlighting the need for more targeted interventions in dietary habits and cognitive health.

Uncover the potential of nivolumab and axicabtagene ciloleucel as they showcase promising results in the latest lymphoma trials, potentially reshaping the standard of care for these malignancies.

Innovations in mRCC management are accelerating, and significant shifts have already begun with the ODYSSEY RCC study and the first-ever comprehensive ASCO guidelines for metastatic clear-cell RCC – read on to stay ahead of the curve.

The phase 3 trial findings underscore the potential of axi-cel as a robust second-line treatment for early relapsed or refractory large B-cell lymphoma, providing promising strides in improving patient survival rates.

Learn about a ground-breaking strategy for treating uncommon brain tumors like papillary craniopharyngiomas (PCPs), where precision medicine and BRAF/MEK inhibitors marked a major improvement in brain cancer treatment by drastically reducing tumor size.